The Guardant360 test is helping advanced breast cancer patients get the right treatment with a simple blood draw. In this patient case, the Guardant360 test detected a treatable alteration, PIK3CA, in a 45-year-old breast cancer patient when tissue biopsy was difficult to process due to metastasis to the bone. Treated with the right precision medicine, alpelisib, combined with fulvestrant, the patient responded well to treatment. This is an actual patient case, but the image and name are not real to maintain patient’s confidentiality.

Visit us online @ guardanthealthamea.com

to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360. Guardant360®. Test. Take Action.